Calidi Biotherapeutics, Inc.CLDINYSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank18
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P18
Within normal range
vs 3Y Ago
-3.1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -26.41% |
| Q2 2025 | 16.46% |
| Q1 2025 | 45.05% |
| Q4 2024 | -40.84% |
| Q3 2024 | -14.76% |
| Q2 2024 | -0.83% |
| Q1 2024 | -33.89% |
| Q4 2023 | 42.07% |
| Q3 2023 | 29.17% |
| Q2 2023 | 14.83% |
| Q1 2023 | -60.62% |
| Q4 2022 | 110.92% |
| Q3 2022 | 8.39% |
| Q2 2022 | -15.71% |
| Q1 2022 | 76.76% |
| Q4 2021 | 77.65% |
| Q3 2021 | 10848.80% |
| Q2 2021 | 0.00% |